Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate

Head and Neck

Volumn 37, Issue 1, 2015, Pages 134-150

  Strojan, Primož ^a   Corry, June ^b   Eisbruch, Avraham ^c   Vermorken, Jan B ^d   Mendenhall, William M ^e   Lee, Anne W M ^f   Haigentz, Missak ^g   Beitler, Jonathan J ^h   De Bree, Remco ⁱ   Takes, Robert P ^j   Paleri, Vinidh ^k   Kelly, Charles G ^l   Genden, Eric M ^m   Bradford, Carol R ⁿ   Harrison, Louis B ^o   Rinaldo, Alessandra ^p   Ferlito, Alfio ^p  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MICHIGAN   (United States)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF FLORIDA   (United States)

^f THE UNIVERSITY OF HONG KONG SHENZHEN HOSPITAL   (China)

^g MONTEFIORE MEDICAL CENTER   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^l FREEMAN HOSPITAL   (United Kingdom)

^m MOUNT SINAI MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^o BETH ISRAEL MEDICAL CENTER   (United States)

^p UNIVERSITY OF UDINE   (Italy)

more..

Author keywords

Head and neck cancer; Recurrence; Reirradiation; Salvage surgery; Second primary cancer; Squamous cell carcinoma; Systemic therapy

Indexed keywords

CETUXIMAB; FLUOROURACIL; PLATINUM;

BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMORBIDITY; DATA BASE; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MORBIDITY; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RETREATMENT; REVIEW; SALVAGE THERAPY; SECOND CANCER; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; SYSTEMIC THERAPY; THERAPY EFFECT; TREATMENT INDICATION; TUMOR VOLUME; CARCINOMA, SQUAMOUS CELL; COMPUTER ASSISTED RADIOTHERAPY; HEAD AND NECK NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; RADIATION DOSE;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PATIENT SELECTION; RADIOTHERAPY DOSAGE; RADIOTHERAPY, COMPUTER-ASSISTED; RETREATMENT; SALVAGE THERAPY;

EID: 84918774555     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23542     Document Type: Review

References (114)

1. Scala LM, Hu K, Urken ML, et al. Intraoperative high-dose-rate radiotherapy in the management of locoregionally recurrent head and neck cancer. Head Neck 2013;35:485-492.
2. Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011;100:33-40.
3. Wong LY, Wei WI, Lam LK, Yuen AP. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 2003;25:953-959.
4. Taussky D, Dulguerov P, Allal AS. Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas. Head Neck 2005;27:182-186.
5. Bachar GY, Goh C, Goldstein DP, O'Sullivan B, Irish JC. Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy. Eur Arch Otorhinolaryngol 2010;267:295-301.
6. Nichols AC, Kneuertz PJ, Deschler DG, et al. Surgical salvage of the oro-pharynx after failure of organ-sparing therapy. Head Neck 2011;33:516-524.
7. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6:963-968.
8. Wang Z, Sturgis EM, Zhang F, et al. Genetic variants of p27 and p21 as predictors for risk of second primary malignancy in patients with index squamous cell carcinoma of head and neck. Mol Cancer 2012;11:17.
9. Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989;17: 449-456.
10. Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol 2001;19:1358-1362.
11. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000;110(Suppl 93):1-18.
12. Kim AJ, Suh JD, Sercarz JA, et al. Salvage surgery with free flap reconstruction: factors affecting outcome after treatment of recurrent head and neck squamous carcinoma. Laryngoscope 2007;117:1019-1023.
13. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
14. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004;101:2222-2229.
15. Paleri V, Kelly CG. Reirradiation with concurrent chemotherapy in recurrent head and neck cancer: a decision analysis model based on a systematic review. Clin Otolaryngol 2008;33:331-337.
16. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008;26:5518-5523.
17. Emami B, Bignardi M, Spector GJ, Devineni VR, Hederman MA. Reirra-diation of recurrent head and neck cancers. Laryngoscope 1987;97:85-88.
18. Benchalal M, Bachaud JM, François P, et al. [Hyperfractionated reirradia-tion after salvage surgery in cervico-facial carcinoma. Result of a pilot study in 14 patients]. [Article in French] Cancer Radiother 1997;1:68-73.
19. Nag S, Schuller DE, Martinez-Monge R, Rodriguez-Villalba S, Grecula J, Bauer C. Intraoperative electron beam radiotherapy for previously irradiated advanced head and neck malignancies. Int J Radiat Oncol Biol Phys 1998;42:1085-1089.
20. De Crevoisier R, Domenge C, Wibault P, et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 2001;91:2071-2076.
21. Machtay M, Rosenthal DI, Chalian AA, et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59: 72-77.
22. Kasperts N, Slotman BJ, Leemans CR, de Bree R, Doornaert P, Langendijk JA. Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer 2006;106:1536-1547.
23. Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006;64:382-391.
24. Suh JD, Kim BP, Abemayor E, et al. Reirradiation after salvage surgery and microvascular free flap reconstruction for recurrent head and neck carcinoma. Otolaryngol Head Neck Surg 2008;139:781-786.
25. Janssen S, Baumgartner M, Bremer M, et al. Reirradiation of head and neck cancer-impact of total dose on outcome. Anticancer Res 2010;30: 3781-3786.
26. Tortochaux J, Tao Y, Tournay E, et al. Randomized phase III trial (GOR-TEC 98-03) comparing reirradiation plus chemotherapy versus metho-trexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with palliative intent. Radiother Oncol 2011;100:70-75.
27. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008;30:281-288.
28. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose pacli-taxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 2007;25:4800-4805.
29. Skołyszewski J, Korzeniowski S, Reinfuss M. The radiation of recurrences of head and neck cancer. Br J Radiol 1980;53:462-465.
30. Langlois D, Eschwege F, Kramar A, Richard JM. Reirradiation of head and neck cancers. Presentation of 35 cases treated at the Gustave Roussy Institute. Radiother Oncol 1985;3:27-33.
31. Levendag PC, Meeuwis CA, Visser AG. Reirradiation of recurrent head and neck cancers: external and/or interstitial radiation therapy. Radiother Oncol 1992;23:6-15.
32. Wang CC, McIntyre J. Reirradiation of laryngeal carcinoma-techniques and results. Int J Radiat Oncol Biol Phys 1993;26:783-785.
33. Tercilla OF, Schmidt-Ullrich R, Wazer DE. Reirradiation of head and neck neoplasms using twice-a-day scheduling. Strahlenther Onkol 1993; 169:285-290.
34. Stevens KR Jr, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 1994;29: 687-698.
35. Hartsell WF, Thomas CR Jr, Murthy AK, Taylor SG IV, Haselow RE. Pilot study for the evaluation of simultaneous cisplatin/5-fluorouracil infusion and limited radiation therapy in regionally recurrent head and neck cancer (EST P-C385). Am J Clin Oncol 1994;17:338-343.
36. De Crevoisier R, Bourhis J, Domenge C, et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998;16:3556-3562.
37. Spencer SA, Wheeler RH, Peters GE, et al. Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. Am J Clin Oncol 1999;22:1-5.
38. Schaefer U, Micke O, Schueller P, Willich N. Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemo-therapy and radiation therapy-results of a prospective study. Radiology 2000;216:371-376.
39. Dawson LA, Myers LL, Bradford CR, et al. Conformal reirradiation of recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:377-385.
40. Ohizumi Y, Tamai Y, Imamiya S, Akiba T. Prognostic factors of reirradiation for recurrent head and neck cancer. Am J Clin Oncol 2002;25: 408-413.
41. Spencer S, Wheeler R, Peters G, et al. Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer. Head Neck 2003;25:118-122.
42. Nagar YS, Singh S, Datta NR. Chemo-reirradiation in persistent/recurrent head and neck cancers. Jpn J Clin Oncol 2004;34:61-68.
43. Kramer NM, Horwitz EM, Cheng J, et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractio-nated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck 2005;27:406-414.
44. Langendijk JA, Kasperts N, Leemans CR, Doornaert P, Slotman BJ. A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother Oncol 2006;78:306-312.
45. Cohen EE, Rosine D, Haraf DJ, et al. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007;67:678-684.
46. Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil-and hydroxyurea-based concomitant chemoradio-therapy for poor-prognosis head and neck cancer. J Clin Oncol 2008;26: 1732-1741.
47. Watkins JM, Shirai KS, Wahlquist AE, et al. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck 2009;31:493-502.
48. Berger B, Belka C, Weinmann M, Bamberg M, Budach W, Hehr T. Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma: update of a single-center prospective phase II protocol. Strahlenther Onkol 2010;186:255-261.
49. Platteaux N, Dirix P, Vanstraelen B, Nuyts S. Outcome after reirradiation of head and neck cancer patients. Strahlenther Onkol 2011;187:23-31.
50. Balermpas P, Keller C, Hambek M, et al. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. Int J Radiat Oncol Biol Phys 2012;83:e377-e383.
51. Vormittag L, Lemaire C, Radonjic D, Kornek G, Selzer E. Reirradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial. Strahlenther Onkol 2012;188:235-242.
52. Hamoir M, Ferlito A, Schmitz S, et al. The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol 2012;48:203-210.
53. Kuhn E, Molnar Z, Bohm K. Postirradiation changes on the lymphatics studied by lymphography. Rofo 1979;131:92-96.
54. Jonsson K, Libshitz HI, Osborne BM. Lymphangiographic changes after radiation therapy. AJR Am J Roentgenol 1978;131:803-806.
55. Burge JS. Histological changes in cervical lymph nodes following clinical irradiation. Proc R Soc Med 1975;68:77-79.
56. Flach GB, Broglie MA, van Schie A, et al. Sentinel node biopsy for oral and oropharyngeal squamous cell carcinoma in the previously treated neck. Oral Oncol 2012;48:85-89.
57. Popovtzer A, Gluck I, Chepeha DB, et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys 2009;74:1342-1347.
58. de Bree R, Deurloo EE, Snow GB, Leemans CR. Screening for distant metastases in patients with head and neck cancer. Laryngoscope 2000; 110:397-401.
59. Chen YJ, Kuo JV, Ramsinghani NS, Al-Ghazi MS. Intensity-modulated radiotherapy for previously irradiated, recurrent head-and-neck cancer. Med Dosim 2002;27:171-176.
60. Lee N, Chan K, Bekelman JE, et al. Salvage reirradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:731-740.
61. Biagioli MC, Harvey M, Roman E, et al. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:1067-1073.
62. Goldstein DP, Karnell LH, Yao M, Chamberlin GP, Nguyen TX, Funk GF. Outcomes following reirradiation of patients with head and neck cancer. Head Neck 2008;30:765-770.
63. Sulman EP, Schwartz DL, Le TT, et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009;73:399-409.
64. Duprez F, Madani I, Bonte K, et al. Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol 2009;93:563-569.
65. Sher DJ, Haddad RI, Norris CM Jr, et al. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer 2010;116:4761-4768.
66. Zwicker F, Roeder F, Hauswald H, et al. Reirradiation with intensity-modulated radiotherapy in recurrent head and neck cancer. Head Neck 2011;33:1695-1702.
67. Chen AM, Farwell DG, Luu Q, Cheng S, Donald PJ, Purdy JA. Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011;80:669-676.
68. Zygogianni A, Kyrgias G, Kouvaris J, et al. Reirradiation in head and neck cases using IMRT technique: a retrospective study with toxicity and survival report. Head Neck Oncol 2012;4:78.
69. Kharofa J, Choong N, Wang D, et al. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmeta-static squamous cell carcinoma of the head-and-neck. Int J Radiat Oncol Biol Phys 2012;83:690-695.
70. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryng-eal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004;233:93-100.
71. Wang K, Heron DE, Clump DA, et al. Target delineation in stereotactic body radiation therapy for recurrent head and neck cancer: a retrospective analysis of the impact of margins and automated PET-CT segmentation. Radiother Oncol 2013;106:90-95.
72. Dagan R, Morris CG, Kirwan JM, et al. Elective neck dissection during salvage surgery for locally recurrent head and neck squamous cell carcinoma after radiotherapy with elective nodal irradiation. Laryngoscope 2010;120:945-952.
73. Wax MK, Touma BJ. Management of the N0 neck during salvage laryn-gectomy. Laryngoscope 1999;109:4-7.
74. Temam S, Koka V, Mamelle G, et al. Treatment of the N0 neck during salvage surgery after radiotherapy of head and neck squamous cell carcinoma. Head Neck 2005;27:653-658.
75. Yao M, Roebuck JC, Holsinger FC, Myers JN. Elective neck dissection during salvage laryngectomy. Am J Otolaryngol 2005;26:388-392.
76. Farrag TY, Lin FR, Cummings CW, et al. Neck management in patients undergoing postradiotherapy salvage laryngeal surgery for recurrent/persistent laryngeal cancer. Laryngoscope 2006;116:1864-1866.
77. Yirmibesoglu E, Fried D, Shores C, et al. Incidence of subclinical nodal disease at the time of salvage surgery for locally recurrent head and neck cancer initially treated with definitive radiation therapy. Am J Clin Oncol 2013;36:475-480.
78. Falchook AD, Dagan R, Morris CG, Mendenhall WM. Elective neck dissection for second primary after previous definitive radiotherapy. Am J Otolaryngol 2012;33:199-204.
79. Amit M, Hilly O, Leider-Trejo L, et al. The role of elective neck dissection in patients undergoing salvage laryngectomy. Head Neck 2013;35: 1392-1396.
80. Solares CA, Fritz MA, Esclamado RM. Oncologic effectiveness of selective neck dissection in the N0 irradiated neck. Head Neck 2005;27:415-420.
81. Lee DJ, Kwon KH, Chung EJ, Park IS, Kim JH, Rho YS. The role of elective neck dissection during salvage surgery in head and neck squamous cell carcinoma. Acta Otolaryngol 2013;133:886-892.
82. Chopra S, Gupta T, Agarwal JP, Budrukkar A, Ghosh-Laskar S, Dinshaw K. Reirradiation in the management of isolated neck recurrences: current status and recommendations. Radiother Oncol 2006;81:1-8.
83. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368: 843-854.
84. Tanvetyanon T, Padhya T, McCaffrey J, et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol 2009;27:1983-1991.
85. Ang KK, Jiang GL, Feng Y, Stephens LC, Tucker SL, Price RE. Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys 2001;50:1013-1020.
86. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl): S42-S49.
87. Nieder C, Grosu AL, Andratschke NH, Molls M. Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. Int J Radiat Oncol Biol Phys 2006;66:1446-1449.
88. Chen CC, Lee CC, Mah D, et al. Dose sparing of brainstem and spinal cord for reirradiating recurrent head and neck cancer with intensity-modulated radiotherapy. Med Dosim 2011;36:21-27.
89. Stoiber EM, Schwarz M, Debus J, Huber PE, Bendl R, Giske K. Regional cumulative maximum dose to the spinal cord in head-and-neck cancer: consideration for re-treatment. Radiother Oncol 2013;106:96-100.
90. McDonald MW, Moore MG, Johnstone PA. Risk of carotid blowout after reirradiation of the head and neck: a systematic review. Int J Radiat Oncol Biol Phys 2012;82:1083-1089.
91. Choe KS, Haraf DJ, Solanki A, et al. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer 2011; 117:4671-4678.
92. Unger KR, Lominska CE, Deeken JF, et al. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010;77:1411-1419.
93. Cengiz M, Ozyigit G, Yazici G, et al. Salvage reirradiation with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011;81:104-109.
94. Siddiqui F, Patel M, Khan M, et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys 2009;74:1047-1053.
95. Roh KW, Jang JS, Kim MS, et al. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2009;74:1348-1355.
96. Heron DE, Ferris RL, Karamouzis M, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalationtrial. Int J Radiat Oncol Biol Phys 2009;75:1493-1500.
97. Heron DE, Rwigema JC, Gibson MK, Burton SA, Quinn AE, Ferris RL. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. Am J Clin Oncol 2011;34:165-172.
98. Kodani N, Yamazaki H, Tsubokura T, et al. Stereotactic body radiation therapy for head and neck tumor: disease control and morbidity outcomes. J Radiat Res 2011;52:24-31.
99. Comet B, Kramar A, Faivre-Pierret, et al. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2012;84:203-209.
100. Iwata H, Tatewaki K, Inoue M, Yokota N, Sato K, Shibamoto Y. Salvage stereotactic reirradiation using the CyberKnife for the local recurrence of nasal or paranasal carcinoma. Radiother Oncol 2012;104:355-360.
101. Shikama N, Kumazaki Y, Tsukamoto N, et al. Validation of nomogram-based prediction of survival probability after salvage reirradiation of head and neck cancer. Jpn J Clin Oncol 2013;43:154-160.
102. Paleri V, Roe JWG, Strojan P, et al. Strategies to reduce long-term post-chemoradiation dysphagia in patients with head and neck cancer: an evidence-based review. HeadNeck 2013. [Epub ahead of print].
103. Wang ZH, Zhang SZ, Zhang ZY, et al. Protecting the oral mucosa in patients with oral tongue squamous cell carcinoma treated postoperatively with intensity-modulated radiotherapy: a randomized study. Laryngoscope 2012;122:291-298.
104. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12:127-136.
105. Ozyigit G, Cengiz M, Yazici G, et al. A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of local recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e263-e268.
106. Bottke D, Bathe K, Wiegel T, Hinkelbein W. Phase I trial of radiochemo-therapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol 2007;183:128-132.
107. Kubicek GJ, Axelrod RS, Machtay M, et al. Phase I trial using the protea-some inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2012;83:1192-1197.
108. Rusthoven KE, Feigenberg SJ, Raben D, et al. Initial results of a phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010;78:1020-1025.
109. Kao J, Genden EM, Chen CT, et al. Phase I trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 2011;117:3173-3181.
110. Langer CJ, Duffy K, Horwitz EM, et al. Phase I trial of concurrent hyper-fractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naive locally advanced upper aerodigestive malignancy. Cancer Invest 2006;24:164-173.
111. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354: 567-578.
112. Vargo JA, Heron DE, Ferris RL, et al. Prospective evaluation of patient-reported quality-of-life outcomes following SBRT ± cetuximab for locally-recurrent, previously-irradiated head and neck cancer. Radiother Oncol 2012;104:91-95.
113. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinoma (HNC). J Clin Oncol 2011;29(Suppl):360s (abstract 5500).
114. Yamazaki H, Kodani N, Ogita M, Sato K, Himei K. Reirradiation of head and neck cancer focusing on hypofractionated stereotactic body radiation therapy. Radiat Oncol 2011;6:98.